{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:46:25Z","timestamp":1788839185461,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.xphs.2021.12.020","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T03:03:31Z","timestamp":1640315011000},"page":"1325-1334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A Systematic Approach to Evaluating Closed System Drug-Transfer Devices During Drug Product Development"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2967-5522","authenticated-orcid":false,"given":"Sanket","family":"Patke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6794-5197","authenticated-orcid":false,"given":"Erika Naumann","family":"Gaillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Calero-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamera B.","family":"Gooding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heloise","family":"Audat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Leman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasco","family":"Filipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2021.12.020_bib0001","article-title":"Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners","author":"Khaira","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"10.1016\/j.xphs.2021.12.020_bib0002","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.12968\/bjon.2020.29.10.S15","article-title":"Use of a closed-system drug transfer device reduces contamination with doxorubicin during bolus injection","volume":"29","author":"Marler-Hausen","year":"2020","journal-title":"Br J Nurs"},{"issue":"7","key":"10.1016\/j.xphs.2021.12.020_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159052","article-title":"Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug-compounding unit: a prospective, controlled, parallel study","volume":"11","author":"Simon","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.xphs.2021.12.020_bib0004","unstructured":"The National Institute for Occupational Safety and Health (NIOSH). NIOSH DRAFT list of hazardous drugs in healthcare settings. 2020. Available at: https:\/\/www.cdc.gov\/niosh\/docket\/review\/docket233c\/default.html. Accessed May 21, 2020."},{"key":"10.1016\/j.xphs.2021.12.020_bib0005","unstructured":"United States Pharmacopeia. USP General Chapter <800>, Hazardous Drugs - Handling in Healthcare Settings. USP42-NF37 Ed.2021"},{"issue":"1","key":"10.1016\/j.xphs.2021.12.020_bib0006","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.xphs.2019.10.042","article-title":"Challenges of using closed system transfer devices with biological drug products: an industry perspective","volume":"109","author":"Sreedhara","year":"2020","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2021.12.020_bib0007","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.xphs.2020.10.047","article-title":"An industry perspective on compatibility assessment of closed system drug-transfer devices for biologics","volume":"110","author":"Besheer","year":"2021","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2021.12.020_bib0008","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.xphs.2021.02.008","article-title":"An industry perspective on the challenges of using closed system transfer devices with biologics and communication guidance to healthcare professionals","volume":"110","author":"Gopalrathnam","year":"2021","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2021.12.020_bib0009","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1016\/j.xphs.2020.07.031","article-title":"Determination of holdup volume and transient contact compatibility of closed system transfer devices for a reconstituted lyophilized drug product","volume":"109","author":"Kagdi","year":"2020","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2021.12.020_bib0010","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.xphs.2019.07.021","article-title":"Overcoming challenges of implementing closed system transfer device clinical in-use compatibility testing for drug development of antibody drug conjugates","volume":"109","author":"Petoskey","year":"2020","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2021.12.020_bib0011","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11095-020-02784-1","article-title":"Evaluation of different quality-relevant aspects of closed system transfer devices (CSTDs)","volume":"37","author":"Besheer","year":"2020","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2021.12.020_bib0012","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/1078155218781900","article-title":"Comparison of closed system transfer devices for turnaround time and ease of use","volume":"25","author":"Nurgat","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.xphs.2021.12.020_bib0013","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/vco.12148","article-title":"Treatment time, ease of use and cost associated with use of Equashield\u2122, PhaSeal\u00ae, or no closed system transfer device for administration of cancer chemotherapy to a dog model","volume":"15","author":"Kicenuik","year":"2017","journal-title":"Vet Comp Oncol"},{"issue":"1","key":"10.1016\/j.xphs.2021.12.020_bib0014","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/2193-1801-2-273","article-title":"Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital","volume":"2","author":"Miyake","year":"2013","journal-title":"Springerplus"},{"issue":"5","key":"10.1016\/j.xphs.2021.12.020_bib0015","first-page":"431","article-title":"Use of a closed-system drug transfer device (PhaSeal) and impact on preparation time","volume":"16","author":"Sanchez-Rubio Ferrandez","year":"2012","journal-title":"Int J Pharm Compd"},{"issue":"1","key":"10.1016\/j.xphs.2021.12.020_bib0016","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5731\/pdajpst.2018.008664","article-title":"A case study to address a gap in the device-to-vial interface stopper push-in by chemo spikes","volume":"73","author":"Zhao","year":"2019","journal-title":"PDA J Pharm Sci Technol"},{"issue":"3","key":"10.1016\/j.xphs.2021.12.020_bib0017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1208\/s12248-019-0312-3","article-title":"Interfacial stress in the development of biologics: fundamental understanding, current practice, and future perspective","volume":"21","author":"Li","year":"2019","journal-title":"AAPS J"},{"issue":"5","key":"10.1016\/j.xphs.2021.12.020_bib0018","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.xphs.2016.02.019","article-title":"Silicone oil microdroplets can induce antibody responses against recombinant murine growth hormone in mice","volume":"105","author":"Chisholm","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2021.12.020_bib0019","unstructured":"USP<1151>pharmaceutical dosage Forms USP42-NF37 2S. Available at:https:\/\/www.online.uspnf.com\/uspnf\/document\/1_GUID-431F93A9-1FEC-42AE-8556-AA5B604B2E36_6_en-USsource. Accessed May 21, 2020."},{"key":"10.1016\/j.xphs.2021.12.020_bib0020","series-title":"Guidance to Industry: Allowable Excess Volume Labeled Vial Fill Size Injectable. Drug Biol Products","year":"2015"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921006985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921006985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:36:32Z","timestamp":1758360992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921006985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0022354921006985"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.12.020","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Approach to Evaluating Closed System Drug-Transfer Devices During Drug Product Development","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}